Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

Roche

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Roche's 2013 sales performance.

Roche

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

Roche has revealed new data from various late-stage trials evaluating its AbbVie-partnered BCL-2 inhibitor Venclyxto, including four-year follow-up analysis from the phase 3 CLL14 study. . ... head of global product development, Roche.

Targacept picks Solvay's Stephen Hill to fill vacant CEO post

Targacept picks Solvay's Stephen Hill to fill vacant CEO post Prior to that, he served at US biotech ArQule and Roche, where he held several leadership positions including global head of clinical development.

Finalists 2021

by Lexington. for Roche Diagnostics. Heart Failure: The Hidden Costs of Late Diagnosis. ... by Lexington. for Roche Diagnostics. Creating a movement in dermatology: Clear Horizons UK.

J&J exits $1.6bn blood cancer drug licensing deal with argenx

J&J exits $1.6bn blood cancer drug licensing deal with argenx The ongoing, early-stage trial is evaluating cusatuzumab in combination with AbbVie/Roche’s Venclexta (venetoclax) and chemotherapy Vidaza (azacitidine) in newly-diagnosed, elderly patients with AML.

EC approves Venclyxto-based combinations for newly diagnosed AML

EC approves Venclyxto-based combinations for newly diagnosed AML The European Commission (EC) has approved Roche and AbbVie’s Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who can’t ... for, intensive chemotherapy,” said Levi

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

The power of communication: Engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....